Merck CDR (CAD Hedged) (MRK)

Merck CDR (CAD Hedged) (MRK $24.86)
- $24.86 P/E (TTM): 15.14X Cap: $379.93B
- View MRK Profile
- View Questions on MRK

{tplLang.businessdescription | toLang tLang}

{ profileData.description }

{tplLang.details | toLang tLang}

{tplLang.ceo | toLang tLang}

{profileData.profile.details.ceo}

{tplLang.employees | toLang tLang}

{profileData.profile.details.employees | numeraljs '0,0'}

{tplLang.issuetype | toLang tLang}

{profileData.profile.details.issuetype | asIssueType}

{tplLang.industryclassifications | toLang tLang}

{tplLang.sector | toLang tLang}

{profileData.profile.classification.sector}

{tplLang.industry | toLang tLang}

{profileData.profile.classification.industry}

{tplLang.toolname| toLang tLang}

There is no {tplLang.toolname| toLang tLang} currently available for {data.symbolstring}.

Becton Dickinson and Company (BDX $145.30)
- $145.30 P/E (TTM): 24.55X Cap: $42.57B
- View BDX Profile
- View Questions on BDX
Stryker Corporation (SYK $314.86)
- $314.86 P/E (TTM): 39.07X Cap: $123.10B
- View SYK Profile
- View Questions on SYK
Waters Corporation (WAT $291.74)
- $291.74 P/E (TTM): 27.86X Cap: $29.52B
- View WAT Profile
- View Questions on WAT
Zoetis Inc. Class A (ZTS $114.13)
- $114.13 P/E (TTM): 19.58X Cap: $49.06B
- View ZTS Profile
- View Questions on ZTS
Pfizer CDR (CAD Hedged) (PFE $11.80)
- $11.80 P/E (TTM): 19.7X Cap: $208.22B
- View PFE Profile
- View Questions on PFE
Merck CDR (CAD Hedged) (MRK $24.86)
- $24.86 P/E (TTM): 15.14X Cap: $379.93B
- View MRK Profile
- View Questions on MRK

Q: As portfolios should be diversified, the following names are owned, yet are not doing well, except SYK/MRK. Are any of these outright sells or just not the flavour of the day?Thank you for your excellent advice!

Read Answer Asked by Neil on April 29, 2026